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INTRODUcIION
FOR the past few years the policy in most transplantation centres has been to
allocate cadaver kidneys to recipients whose tissues are antigenically similar to the
donor's. Tissue similarity has been assessed by comparison of the HL-A antigens
identifiable on lymphocytes i(not kidney or other tissue cells) from donor and
recipient. The technique of HL-A typing is not in itself difficult. Briefly, lymphocyte
suspensions are prepared from freshly drawn peripheral blood by flotation on a
Triosil-Ficoll solution (Harris and Ukaejiofo, 1969). After washing with buffered
saline, the suspensions are added to tissue typing plates which have been primed
with sera and covered with liquid paraffin to prevent evaporation. Each plate has
spaces for up to 72 sera. After incubation, complement, in the form of a mixture of
rabbit and human serum, is added to each test and a further incubation carried out.
In those tests where lymphocyte antigens have reacted with the sera, complement
activation results in cell death. Microscopic examination after the addition of trypan
blue (which stains the killed cells but is excluded from living ones) enables positive
tests to be identified.
In common with most of the tissue typing laboratories in Great Britain, we
receive our sera from the National Tissue Typing Reference Laboratory
(N.T.T.R.L.) in Bristol. This has the advantage that donors and recipients through-
out Britain are, in the main, typed with the same sera. The HL-A antisera in use
are mainly obtained from women during pregnancy who become immunised to
HL-A antigens inherited by the foetus from the father. Antibody-containing sera
are identified by the same basic method as for HL-A typing, except that cells of
known antigen content from a panel of volunteers (members of staff) are tested
against sera of unknown antibody content. Most tissue typing laboratories, including
our own, carry out a screening programme on pregnancy sera as part of their
routine work. Potentially useful sera are submitted to N.T.T.R.L. who carry out
further tests, and may request further supplies of the test sera.
In parallel with the antibody screening programme, serum samples from pros-
pective kidney recipients are also tested. This is of importance, since antibodies
in a recipient's serum may cause immediate rejection of an incompatible transplant.
They are in general weak antibodies, and are difficult to characterise.
48The work of the tissue typing laboratory thus comprises three parts, namely
HR-A typing for transplantation, serom supply, and transplant recipient screening
for HD--A antibodies. We present below some of our findings during the three year
period, September 1971-August 1974.
HL-A TYPING
During the three year period 64 potential kidney recipients were typed. A further
48 patients, potential kidney donors, were also typed; and in the establishment of
the antibody screening programme cells from a staff panel numbering 108 were
tested, most of them during late 1973 and early 1974. We were, therefore, able to
type the staff panel with an improved range of sera for antigens in the W19 com-
plex, earlier tests being relatively insensitive for these factors. Since there is at
present much interest in the distribution of the HL-A antigens in various diseases
and conditions of stress, we have compared the antigen frequencies in our prospec-
tive kidney recipients and potential donors, and in our staff panel with the Bristol
blood donor panel reported by Nelson, Darke and Tovey (1974). Table I shows the
antigen frequencies in the four groups.
TABLE I
HL-A antigen frequencies in kidney recipients, donors, and hospital staff,
compared with a blood donor panel (Nelson et al, 1974). Chi squared values
greater than 8.0 (with Yates' correction) are indicated
Kidney Recipients Kidney Donors Bristol Blood
HL-A (Actual + Potential) (Actual + Potential) Staff Panel Donor Panel
N=64 N=48 N=108 N=1036
No. % No. % No. % No. %
1 25 39 20 42 42 39 348 34
2 38 59 24 50 52 48 536 52
3 14 22 14 29 25 23 265 26
9 11 17 13 27 15 14 190 18
10 6 9.4 4 8.3 6 5.6 87 8.4
11 6 9.4 2 4.2 12 11 106 10
W28 0 2 4.2 9 8.3 38 3.7
W19 10 5.6 2 4.2 26 24 175 17
5 3 4.7 3 6.3 9 8.3 87 8.4
7 19 30 19 40 32 30 265 26
8 22 34 16 33 23 21 260 25
12 16 25 13 27 t46 42 254 24
13 1 1.6 1 2.1 3 2.8 45 4.3
W5 8 13 6 13 6 7 114 11
W10 8 13 6 13 15 14 116 11
W14 5 7.8 4 8.3 3 2.8 72 7
W15 9 14* 1 2.1 11 10 50 4.8
W17 7 11 4 8 11 10 79 7.6
W18 5 7.8 3 6.3 2 1.91 35 3.4
W21 1 1.6 1 2.1 1 0.9 18 1.7
W22 2 3.1 1 2.1 3 2.8 55 5.3
W27 5 7.8 2 4.2 10 9.3 77 7.4
*Chi squared=8.39; 0.005>p>0.001; after correction 0.115>p>0.023
tChi squared=15.56; p<0.0005; after correction <0.015
49When the same population samples are compared several times, the chance of
finding a "statistically significant" difference increases with the number of com-
parisons. Accordingly, in assessing the significance of inter-sample differences, the
p value obtained must be corrected by multiplying it by the number of comparisons
(Grumet et al, 1971). In this instance where we have made 23 comparisons, statis-
tical significance will only be maintained if p before correction is less than 0.002;
(Chi squared greater than 9.548).
Under these criteria, the antigen frequencies in our patients and staff showed
few differences from the Bristol blood donors. Surprisingly, the expected reduction
in W19 antigens of the kidney recipients and donors did not achieve statistical
significance; the only finding of significance was that HL-A12 occurred more
frequently in our staff panel than in the Bristol blood donors (Chi squared=15.56).
The fact that our staff panel is, by definition, a selected population sample and not
a random one is the most obvious explanation of the increase in HL-A12, par-
ticularly since population sampling errors tend to be more striking in relatively
small samples.
PREGNANCY SERUM TESTING FOR HL-A ANTIBODIES
Since October 1973 we have screened samples of ante-natal sera kindly supplied
by the Northern Ireland Blood Transfusion Service, and by the Laboratory, Craig-
avon Area Hospital. The sera are obtained from blood grouping specimens taken
routinely during pregnancy, and the test for HL-A antibodies does not involve
taking extra blood from the patients. The frequency with which HUA antibodies
are found in the serum increases with maternal parity, from approximately 5 per
cent in primigravidae, to around 40 per cent in women who have had five or more
pregnancies. Antibodies formed during a first pregnancy are usually weak, although
often of narrow specificity. In subsequent pregnancies, the antibodies may be of
higher titre, and are often directed against more than one antigen. Sera in which
antibodies are found are re-tested in an attempt to define their specificity and titre.
When the antibody is of good titre and monospecific, a further sample (30 ml) is
requested through the courtesy of Col. Field (Northern Ireland Blood Transfusion
Service). The sera from these larger samples are submitted to the National Tissue
Typing Reference Laboratory for confirmation of our findings. If suitable, the sera
are used as HL-A typing reagents. Table II presents a brief statistical summary of
the ante-natal serum screening programme.
ANTIBoDY TESTING OF KIDNEY RECIPIENTS' SERUM
A small proportion of patients awaiting a transplant already have, or may
develop, HL-A antibodies following blood transfusion. Transplantation of an in-
compatible kidney into these patients is usually followed by hyper-acute rejection.
In many cases the antibodies are weak; indeed they may become detectable only
after a pyrexial episode (Nelson et al, 1971). It is therefore important to test
recipients' serum regularly and to carry out a "cross match" using patient's serum
and donor lymphocytes prior to transplantation. By this means, the possibility of a
hyperacute rejection reaction can be avoided.
50TABLE II
Results of Pregnancy Serum Screening
October 1973 - August 1974
Number of Pregnancy sera tested 3,700
Number with HL-A antibodies 460
Per cent with HL-A antibodies 12.4
Larger sample requested for
further investigation 50
Samples sent to N.T.T.R.L. 36
Specificities: HL-A1 (5) HL-A2 (5)
HL-A5 (2) HL-A7 (8)
HL-A8 (4) HL-A12 (6)
W5 (2) W15 (1)
W1O (2) W32 (1)
During the three year period under review, serum samples from 58 patients were
tested for HL-A antibodies. Eleven (19 per cent) were found to be positive, and of
these, seven were awaiting a second transplant. No positive cross matches have been
found and nine of these eleven patients have now received a transplant without
evidence of hyperacute rejection.
COMMENT
The place of HL-A matching for transplantation has not yet been fully assessed;
and while recent reports have suggested that HLA identity between donor and
recipient confers some benefit (Oliver et al, 1972; Van Hooff et al, 1973) there is no
doubt that many kidneys transplanted to recipients of widely different HL-A types
will function for a long time (Belzer et al, 1974). It may be that the emphasis should
be placed on ensuring that kidney recipients are immunised by their transplants
only to low frequency antigens. This policy would have obvious benefits in the
event of a second transplant becoming necessary, because a second donor would
be unlikely to present the recipient with an antigen to which he had already been
immunised.
In the pregnancy serum screening programme our experiences have been similar
to those of Stastny (1972). So far we have identified sera with activity against the
more common HL-A antigens, but we hope in due course to uncover also examples
of the rarer antibodies. Attempts to provide useful sera for our own or for national
use have become more important following the demonstration by Brewerton et al
(1973) of a striking relationship between ankylosing spondylitis and the presence
of the antigen HL-A27. This antigen, present in about 7.5 per cent of healthy
people, is found in more than 90 per cent of sufferers from ankylosing spondylitis;
its presence or absence may be a helpful diagnostic clue, and we can now provide
tests for the presence of this antigen when requested. The use of HU-A typing
tests in various disease states will almost certainly increase during the next few
years, but we hope also for an increase in the number of potential (and actual)
51kidney donors, since successful transplant operations are of benefit not only to the
recipients but may also permit new patients to receive dialysis treatment more
readily.
SUMMARY
The Tissue Typing Laboratory deals mainly with the immunological tests carried
out in relation to renal transplantation. These include HL-A typing of prospective
recipients and donors and testing of recipients' serum for the presence of antibodies
which might cause hyperacute rejection of a transplant. The antisera used for
HL-A typing are usually obtained from pregnant mothers, and most tissue typing
laboratories also test pregnancy sera for potentially useful antibodies by observing
their reactions with cells of known HL-A type.
Between September 1971 and August 1974, 64 potential kidney recipients and
48 possible donors were typed, as were 108 members of staff at the Belfast City
Hospital whose cells were used in antibody detection and identification. The HL-A
antigen frequencies in these three groups were compared with each other and with a
large population of blood donors from the Bristol area. HL-A12 was identified
more frequently in members of staff than in the other groups. This finding is
attributed to the sampling error inherent in selected and relatively small population
samples.
HL-A antibodies were found in 460 (12.4 per cent) of 3700 pregnancy sera; 36
of these were potentially valuable as typing reagents and aliquots were sent to the
National Tissue Typing Reference Laboratory for confirmation of our findings.
The urgency of the task of serum procurement is made more acute by the increase
in requests for tissue typing which has followed recognition of the association
between HL-A27 and ankylosing spondylitis.
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